Luis J Leandro-Garcia
Overview
Explore the profile of Luis J Leandro-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monteagudo M, Calsina B, Salazar-Hidalgo M, Martinez-Montes A, Pineiro-Yanez E, Caleiras E, et al.
Best Pract Res Clin Endocrinol Metab
. 2024 Sep;
38(6):101931.
PMID: 39218714
Pheochromocytomas and paragangliomas are rare neuroendocrine tumours. Around 20-25 % of patients develop metastases, for which there is an urgent need of prognostic markers and therapeutic stratification strategies. The presence...
2.
Roldan-Romero J, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, et al.
Int J Cancer
. 2023 Jun;
153(6):1300-1312.
PMID: 37260183
Mammalian target of rapamycin (mTOR) is a central regulator of mammalian metabolism and physiology. Aberrant hyperactivation of the mTOR pathway promotes tumor growth and metastasis, and can also promote tumor...
3.
Calsina B, Pineiro-Yanez E, Martinez-Montes A, Caleiras E, Fernandez-Sanroman A, Monteagudo M, et al.
Nat Commun
. 2023 Feb;
14(1):1122.
PMID: 36854674
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort of mPPGLs that...
4.
Monteagudo M, Martinez P, Leandro-Garcia L, Martinez-Montes A, Calsina B, Pulgarin-Alfaro M, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638246
One of the main problems we face with PPGL is the lack of molecular markers capable of predicting the development of metastases in patients. Telomere-related genes, such as and have...
5.
Mellid S, Coloma J, Calsina B, Monteagudo M, Roldan-Romero J, Santos M, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33182397
Over the past few years, next generation technologies have been applied to unravel the genetics of rare inherited diseases, facilitating the discovery of new susceptibility genes. We recently found germline...
6.
Cordero-Barreal A, Caleiras E, Lopez de Maturana E, Monteagudo M, Martinez-Montes A, Leton R, et al.
J Clin Endocrinol Metab
. 2020 Aug;
105(11).
PMID: 32791518
Context: The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have...
7.
Montero-Conde C, Grana-Castro O, Martin-Serrano G, Martinez-Montes A, Zarzuela E, Munoz J, et al.
Int J Cancer
. 2019 Aug;
146(2):521-530.
PMID: 31403184
It is critical to identify biomarkers and functional networks associated with aggressive thyroid cancer to anticipate disease progression and facilitate personalized patient management. We performed miRNome sequencing of 46 thyroid...
8.
Montero-Conde C, Leandro-Garcia L, Chen X, Oler G, Ruiz-Llorente S, Ryder M, et al.
Proc Natl Acad Sci U S A
. 2017 Jun;
114(25):E4951-E4960.
PMID: 28584132
Oncogenic mutations are present in 15-30% of thyroid carcinomas. Endogenous expression of mutant Ras is insufficient to initiate thyroid tumorigenesis in murine models, indicating that additional genetic alterations are required....
9.
Comino-Mendez I, Leandro-Garcia L, Montoya G, Inglada-Perez L, de Cubas A, Curras-Freixes M, et al.
J Mol Med (Berl)
. 2015 Jun;
93(11):1247-55.
PMID: 26070438
Unlabelled: The presence of germline mutations affecting the MYC-associated protein X (MAX) gene has recently been identified as one of the now 11 major genetic predisposition factors for the development...
10.
Apellaniz-Ruiz M, Lee M, Sanchez-Barroso L, Gutierrez-Gutierrez G, Calvo I, Garcia-Estevez L, et al.
Clin Cancer Res
. 2014 Nov;
21(2):322-8.
PMID: 25398452
Purpose: Paclitaxel, a widely used chemotherapeutic drug, can cause peripheral neuropathies leading to dose reductions and treatment suspensions and decreasing the quality of life of patients. It has been suggested...